Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
EL MONTE, Calif.--(BUSINESS WIRE)--Apr. 11, 2024-- Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business a
Fulgent GeneticsApr 11 00:00 ET
Reproductive Genetics Market Analysis Report 2024-2032, Featuring Bangkok Genomics Innovation, Centogene, Fulgent Genetics, Igenomix, Invitae, PerkinElmer and Thermo Fisher Scientific
Yahoo FinanceMar 28 11:33 ET
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Fulgent Genetics Is Maintained at Neutral by Piper Sandler
Dow JonesMar 6 09:42 ET
Express News | Piper Sandler Maintains Neutral on Fulgent Genetics, Lowers Price Target to $25
Moomoo 24/7Mar 6 09:31 ET
Fulgent Genetics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 7.67% Piper Sandler $28 → $25 Maintains Neutral 12/07/2023 50.73% UBS → $35 Initiates Coverage
BenzingaMar 6 09:31 ET
Piper Sandler Sticks to Its Hold Rating for Fulgent Genetics (FLGT)
TipRanksMar 6 07:36 ET
Revenues Not Telling The Story For Fulgent Genetics, Inc. (NASDAQ:FLGT)
When you see that almost half of the companies in the Healthcare industry in the United States have price-to-sales ratios (or "P/S") below 0.9x, Fulgent Genetics, Inc. (NASDAQ:FLGT) looks to be giving
Simply Wall StMar 1 09:41 ET
An Intrinsic Calculation For Fulgent Genetics, Inc. (NASDAQ:FLGT) Suggests It's 32% Undervalued
Yahoo FinanceMar 1 06:19 ET
Fulgent Genetics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Yahoo FinanceMar 1 05:48 ET
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating
UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating.
MT NewswiresFeb 29 13:00 ET
Express News | Fulgent Genetics Shares Are Trading Lower After the Company Reported Q4 Financial Results and Issued FY24 Guidance Below Estimates
Moomoo 24/7Feb 28 12:07 ET
Earnings Call Summary | Fulgent Genetics(FLGT.US) Q4 2023 Earnings Conference
The following is a summary of the Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript:Financial Performance:Fulgent Genetics reported Q4 revenue of $70 million, an increase compared to Q4 2022's
moomoo AIFeb 28 11:43 ET · Conference Call
Fulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023
Yahoo FinanceFeb 28 07:35 ET
Fulgent Genetics Shares Business Insights in Investor Update
TipRanksFeb 28 07:22 ET
Express News | Fulgent Genetics Expects 2024 Core Revenue of Approximately $280M Versus Consensus Of $294.25M, With Adjusted EPS Loss Of Approximately $(1.05) Versus Consensus Of $(0.95)
Moomoo 24/7Feb 28 07:05 ET
Express News | Fulgent Genetics Q4 Adjusted EPS $0.28 May Not Be Comparable To $(0.29) Estimate, Sales $70.50M Beat $66.32M Estimate
Moomoo 24/7Feb 28 07:02 ET
Press Release: Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results -- Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million -- Full Year 2023 Core Reve
Dow JonesFeb 28 07:02 ET
Fulgent Genetics 4Q Loss $128.1M >FLGT
Fulgent Genetics 4Q Loss $128.1M >FLGT
Dow JonesFeb 28 07:00 ET
Earnings Scheduled For February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. • Golden Ocean Group (NASDAQ:GOGL) is likely to report
BenzingaFeb 28 06:24 ET
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
Full Year 2023 Total Revenue of $289.2 million; Q4 2023 Total Revenue of $70.5 million Full Year 2023 Core Revenue grows 44% year-over-year to $262.1 million; Q4 2023 Core Revenue grows 21% year-ove
Fulgent GeneticsFeb 28 00:00 ET
No Data
No Data